Last reviewed · How we verify

NCT05036447: STYRK DM1

Myotonic Dystrophy Type 1 and Resistance Exercise

Completed NA Last updated 28 November 2023
What this trial tests

NA trial testing Moderate-Heavy Resistance Exercise in Myotonic Dystrophy 1 in 21 participants. Completed in 30 April 2023.

Timeline
14 June 2021
Primary endpoint
30 April 2023
30 April 2023

Quick facts

Lead sponsorNorwegian School of Sport Sciences
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designfactorial
Maskingsingle
Primary purposeother
Enrollment21
Start date14 June 2021
Primary completion30 April 2023
Estimated completion30 April 2023
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Norwegian School of Sport Sciences

Who can join

Adults 18 to 55, any sex, with Myotonic Dystrophy 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the response after one bout of moderate-heavy resistance exercise in patients suffering from Myotonic Dystrophy type 1. There is still doubt about if these patients could benefit from resistance exercise, or if this mode of exercise is detrimental to their mobility and health. We aim to monitor the subjects during the recovery phase and investigate recovery in several ways.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myotonic Dystrophy 1

Currently open trials in the same condition.

Other Norwegian School of Sport Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing